Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer

BACKGROUND: The PARP inhibitor olaparib was recently granted Food and Drug Administration (FDA) accelerated approval in patients with advanced BRCA1/2 mutation ovarian cancer. However, antitumor responses are observed in only approximately 40% of patients and the impact of baseline clinical factors...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Rafii, Saeed, Gourley, Charlie, Kumar, Rajiv, Geuna, Elena, Ang, Joo Ern, Rye, Tzyvia, Chen, Lee-May, Shapira-Frommer, Ronnie, Friedlander, Michael, Matulonis, Ursula, Greve, Jacques De, Oza, Amit M., Banerjee, Susana, Rhoda Molife, L., Gore, Martin E., Kaye, Stan B., Yap, Timothy A.
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5564551/
https://ncbi.nlm.nih.gov/pubmed/28454085
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17005
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados